Evidence map›Paper›PMID 33543004›Full record

ArticleMatrix biology plus2019

Quantitative proteomic profiling of extracellular matrix and site-specific collagen post-translational modifications in an

Juliane Merl-Pham, Trayambak Basak, Larissa Knüppel, Deepak Ramanujam, Mark Athanason, Jürgen Behr, Stefan Engelhardt, Oliver Eickelberg, Stefanie M Hauck, Roberto Vanacore and 1 more

Open access · goldAbstract read
In one paragraph

Article in Matrix biology plus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 83 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Beyond classical collagen: basement membrane collagen IV in age-associated lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  17. Article
  18. Mechanisms and Therapeutic Potential of Myofibroblast Transformation in Pulmonary Fibrosis.Journal of respiratory biology and translational medicine · 2025
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Juliane Merl-PhamResearch Unit Protein Science, Helmholtz Zentrum München, Heidemannstr. 1, 80939 Munich, Germany.
Trayambak BasakCenter for Matrix Biology, Department of Medicine, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN 37232, United States of America.
Larissa KnüppelComprehensive Pneumology Center, Helmholtz-Zentrum München, Max-Lebsche-Platz 31, 81377 Munich, Germany.
Deepak RamanujamInstitut für Pharmakologie und Toxikologie, Technische Universität München (TUM), Munich, Germany.
Mark AthanasonCenter for Matrix Biology, Department of Medicine, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN 37232, United States of America.
Jürgen BehrAsklepios Fachkliniken München-Gauting, Robert-Koch-Allee 2, 82131 Gauting, Germany.
Stefan EngelhardtInstitut für Pharmakologie und Toxikologie, Technische Universität München (TUM), Munich, Germany.
Oliver EickelbergComprehensive Pneumology Center, Helmholtz-Zentrum München, Max-Lebsche-Platz 31, 81377 Munich, Germany.
Stefanie M HauckResearch Unit Protein Science, Helmholtz Zentrum München, Heidemannstr. 1, 80939 Munich, Germany.
Roberto VanacoreCenter for Matrix Biology, Department of Medicine, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN 37232, United States of America.
Claudia A Staab-WeijnitzComprehensive Pneumology Center, Helmholtz-Zentrum München, Max-Lebsche-Platz 31, 81377 Munich, Germany.
Helmholtz Zentrum München · DEVanderbilt University Medical Center · USTechnical University of Munich · DELMU Klinikum · DE

Funding

Novel Integrated Analyses of Human Diabetic NephropathyR24DK103067 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CAPRIOLI, RICHARD M, DENNY, JOSHUA C. · 2014 to 2018
$6.5M
Glucose Modifications of Proteins in Diabetic NephropathyR01DK065138 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HUDSON, BILLY GERALD, VOZIYAN, PAUL A · 2003 to 2020
$6.3M
Vanderbilt O'Brien Kidney Center - Core D - Clinical and Translational CoreP30DK114809 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DE CAESTECKER, MARK P. · 2017 to 2021
$5.9M
VANDERBILT NEPHROLOGY TRAINING PROGRAMT32DK007569 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HARRIS, RAYMOND C., IKIZLER, TALAT ALP · 1988 to 2024
$5.8M
The role of lysyl oxidase like-2 in chronic kidney diseaseR01DK099467 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI VANACORE, ROBERTO MARCELO · 2013 to 2023
$3.8M
NIDDK NIH HHS P30 DK114809NIDDK NIH HHS R01 DK065138NIDDK NIH HHS R01 DK099467NIDDK NIH HHS R24 DK103067NIDDK NIH HHS T32 DK007569
6 · The paper itself

Abstract

Lung fibrosis is characterized by excessive deposition of extracellular matrix (ECM), in particular collagens, by fibroblasts in the interstitium. Transforming growth factor-β1 (TGF-β1) alters the expression of many extracellular matrix (ECM) components produced by fibroblasts, but such changes in ECM composition as well as modulation of collagen post-translational modification (PTM) levels have not been comprehensively investigated. Here, we performed mass spectrometry (MS)-based proteomics analyses to assess changes in the ECM deposited by cultured lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients upon stimulation with transforming growth factor β1 (TGF-β1). In addition to the ECM changes commonly associated with lung fibrosis, MS-based label-free quantification revealed profound effects on enzymes involved in ECM crosslinking and turnover as well as multiple positive and negative feedback mechanisms of TGF-β1 signaling. Notably, the ECM changes observed in this

Indexed as

3-HyP, 3-hydroxyproline4-HyP, 4-hydroxyprolineAGC, automatic gain controlANXA11, annexin A11BGN, biglycanCOL1A1, collagen-I alpha 1 chainCollagenCollagen post-translational modificationsDCN, decorinECM, extracellular matrixExtracellular matrixFN1, fibronectin 1GG-HyK, glucosylgalactosylhydroxylysineG-HyK, galactosylhydroxylysineHyK, hydroxylysineHyP, hydroxyprolineILD, interstitial lung diseaseIPF, idiopathic pulmonary fibrosisLH, lysyl hydroxylaseLOX(L), lysyl oxidase(-like)LTBP2, latent-transforming growth factor β -binding protein 2Lysyl glycosylationLysyl hydroxylationP3H, prolyl-3-hydroxylaseP4H, prolyl-4-hydroxylasePAI1, plasminogen activator inhibitor 1PCA, principal component analysisPLOD (LH), procollagen-lysine,2-oxoglutarate 5-dioxygenases (lysyl hydroxylases)Prolyl hydroxylationPTM, post-translational modificationPulmonary fibrosisSEMA7A, semaphorin 7aTGF-β, transforming growth factor βTGM2, transglutaminase 1Transforming growth factor-βVCAN, versicanXaa, Xaa position in the Gly-Xaa-Yaa repeat in triple-helical collagenYaa, Yaa position in the Gly-Xaa-Yaa repeat in triple-helical collagenα-SMA, α-smooth muscle actin

Identifiers

PMID33543004
PMCPMC7852317
OpenAlexW2939003387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.